Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies Published September 2019 Citation Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR. . ESMO Annual Congress. . https://www.annalsofoncology.org/article/S0923-7534(19)59501-1/pdf Authors:Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR Sources:ESMO Annual Congress Share Posted inPublicationsComparative effectivenessMelanoma More publicationsISPOR 2025April 2025Using regression discontinuity in time design for real-world comparative effectiveness: A case study for the second-line use of pembrolizumab in advanced non-small cell lung cancerChen N, Zemplenyi A, Adamson B, et al. Publication summaryPublicationsComparative effectivenessNon-small cell lung cancerESMO OpenJanuary 2025Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world settingRugo H.S., Layman R.M., Lynce F, et al. Real-world evidencePublication summaryPublicationsComparative effectivenessMetastatic breast cancerCancersMay 2024Sex differences in odds of brain metastasis and outcomes by brain metastasis status after advanced melanoma diagnosisCioffi G, Ascha MS, Waite KA, et al. Publication summaryPublicationsMelanoma